[FORM 10-K (Mark One) December 31, 2012 For the fiscal year ended: For the transition period from ____________to _____________ Commission File No. 001-34566 CHINA BIOLOGIC PRODUCTS, INC. Delaware 75-2308816 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 18th Floor, Jialong International Building, 19 Chaoyang Park Road (+86) 10-6598-3111 Title of each class Name of each exchange] [Consent of Independent Registered Public Accounting Firm The Board of Directors We consent to the incorporation by reference in registration statements (No. 333-171069 and 333-182624) on Form S-3 and the registration statement (No. 333-151263) on Form S-8 of China Biologic Products, Inc. of our reports dated March 13, 2013, with respect to the consolidated balance sheets of China Biologic Products,] [CERTIFICATIONS I, David (Xiaoying) Gao, certify that: 1. I have reviewed this annual report on Form 10-K of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATIONS I, Ming Yang, certify that: 1. I have reviewed this annual report on Form 10-K of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [1. 2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. th] [1. 2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. th Ming Yang (Principal Financial and Accounting Officer)]

[China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2012 FY12 Total Sales Up 20.7% to $184.8 Million FY12 Operating Margin Reaching 40.3% FY12 Non-GAAP Net Income Up 31.5% to $48.0 Million BEIJING, March 13, 2013 /PRNewswire-FirstCall/ -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in] [FORM 8-K CURRENT REPORT Date of Report (Date of Earliest event Reported): November 8, 2012 CHINA BIOLOGIC PRODUCTS, INC. Delaware 001-34566 75-2308816 (State or other jurisdiction of (Commission File No.) (IRS Employer ID No.) incorporation or organization) 18th Floor, Jialong International Building 19 Chaoyang Park Road Chaoyang District, Beijing 100125 People’s Republic of China 86-10-6698-3166 (Former name or former address,]